pipeline
Our pipeline starts with strong science aimed at translating important and central mechanisms of PD development into new medicines.
Agyany is developing first-in-class therapies for Parkinson’s disease, starting with a well-known and proven drug, ambroxol.
Our pipeline
Not Yet Recruiting
Recruiting
Active , Not Recruiting
Completed
agpi
Basic Research/Custom Synthesis
In-Vitro Efficacy
In-Vivo Safety & Efficacy (animal model)
In Human Toxicology
agpi2
Aiming to transform the landscape of Parkinson's disease care, we are relentlessly focused on pioneering novel and universally effective therapies to improve the lives of countless individuals.
References
2022
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease
2006